Ranjana Advani

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Nancy Whiting, R. Advani, A. Younes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Bruce D Cheson, R. Advani, J. Winter, 2014, Journal of Hematology & Oncology.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

Sin-Ho Jung, Arnaud Jaccard, Tohru Murayama, 2016, The Lancet. Oncology.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Roland Schmitz, Chih-Jian Lih, L. Staudt, 2015, Nature Medicine.

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Elaine S. Jaffe, L. Staudt, W. Wilson, 2013, The New England journal of medicine.